```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 16:44:19 ON 10 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 10 Mar 2003  VOL 138 ISS 11
FILE LAST UPDATED: 9 Mar 2003  (20030309/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d l105 all hitstr tot

L105 ANSWER 1 OF 4  HCAPLUS  COPYRIGHT 2003 ACS
AN   2002:575739  HCAPLUS
DN   137:119689
TI   Methods and compositions using a .alpha.3.
     beta.4 nicotinic receptor antagonist combination
     for treating addiction disorders
IN   Glick, Stanley D.; Maisonneuve, Isabelle M.
PA   USA
SO   U.S. Pat. Appl. Publ., 17 pp.
     CODEN: USXXCO
DT   Patent
LA   English
IC   ICM  A61K031-00
NCL  514001000
CC   1-11 (Pharmacology)
     Section cross-reference(s): 63
FAN.CNT 1
     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
PI   US 2002103109      A1   20020801      US 2002-51770    20020118
     WO 2002060425      A1   20020808      WO 2002-US2547   20020129
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI US 2001-264742P   P    20010129
     US 2002-51770     A    20020118
AB   A method for treating an addiction disorder (e.g. an
     addiction to or dependency on stimulants,
     nicotine, morphine, heroin, other
     opiates, amphetamines, cocaine, and/or alc.)
     in a patient is disclosed.  The method includes administering to the
```

patient a first .alpha.3.beta.4 nicotinic receptor antagonist and administering to the patient a second . alpha.3.beta.4 nicotinic receptor antagonist. The second .alpha.3.beta.4 nicotinic receptor antagonist is different than the first . alpha.3.beta.4 nicotinic receptor antagonist, and the first .alpha.3.beta.4 nicotinic receptor antagonist and the second .alpha.3.beta.4 nicotinic receptor antagonist are administered simultaneously or non-simultaneously. Compns. which include a first .alpha.3.beta.4 nicotinic receptor antagonist and a second . alpha.3.beta.4 nicotinic receptor antagonist are also described. Examples of suitable .alpha.3.beta.4 nicotinic receptor antagonists for use in the methods and compns. include mecamylamine, 18-methoxycoronaridine, bupropion, dextromethorphan, dextrorphan, and pharmaceutically acceptable salts and solvates thereof. A method of evaluating a compd. for its effectiveness in treating addiction disorders is also described.

ST alpha3 beta4 nicotinic receptor antagonist combination addiction disorder pharmaceutical; mecamylamine combination addiction disorder pharmaceutical; methoxycoronaridine combination addiction disorder pharmaceutical; bupropion combination addiction disorder pharmaceutical; dextromethorphan combination addiction disorder pharmaceutical; dextrorphan combination addiction disorder pharmaceutical

IT 5-HT receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(5-HT3; .alpha.3.beta.4 nicotinic receptor antagonist combination for treating addiction disorders)

IT Glutamate receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NMDA-binding, NR1/2A and NR1/2B; .alpha.3.beta.4 nicotinic receptor antagonist combination for treating addiction disorders)

IT Drug delivery systems
(capsules; .alpha.3.beta.4 nicotinic receptor antagonist combination for treating addiction disorders)

IT Drug delivery systems
(elixirs; .alpha.3.beta.4 nicotinic receptor antagonist combination for treating addiction disorders)

IT Drug delivery systems
(powders; .alpha.3.beta.4 nicotinic receptor antagonist combination for treating addiction disorders)

IT Behavior
(self-administration; .alpha.3.beta.4 nicotinic receptor antagonist combination for treating addiction disorders)

IT Drug delivery systems
(suspensions; .alpha.3.beta.4 nicotinic receptor antagonist combination for treating addiction disorders)

IT Drug delivery systems
(syrups; .alpha.3.beta.4 nicotinic receptor antagonist combination for treating

addiction disorders)
IT Drug delivery systems
(tablets; .alpha.3.beta.4
nicotinic receptor antagonist combination for treating
addiction disorders)
IT Alcoholism
Drug delivery systems
Drug dependence
Drug interactions
Nicotinic antagonists
(.alpha.3.beta.4 nicotinic
receptor antagonist combination for treating
addiction disorders)
IT Opioids
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)
(.alpha.3.beta.4 nicotinic
receptor antagonist combination for treating
addiction disorders)
IT Nicotinic receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha.3.beta.4 nicotinic
receptor antagonist combination for treating
addiction disorders)
IT 50-36-2, Cocaine 54-11-5, Nicotine
300-62-9, Amphetamine 561-27-3, Heroin
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)
(.alpha.3.beta.4 nicotinic
receptor antagonist combination for treating
addiction disorders)
IT 57-27-2, Morphine, biological studies 64-31-3,
Morphine sulfate 537-46-2, Methamphetamine
28297-73-6, Methamphetamine sulfate
RL: PAC (Pharmacological activity); BIOL (Biological study)
(.alpha.3.beta.4 nicotinic
receptor antagonist combination for treating
addiction disorders)
IT 60-40-2, Mecamylamine 125-69-9,
Dextromethorphan hydrobromide 125-71-3,
Dextromethorphan 125-73-5, Dextrorphan
467-77-6, 18-Methoxycoronaridine
826-39-1, Mecamylamine hydrochloride 34911-55-2
, Bupropion 266686-75-3 266686-77-5
444143-81-1 444143-82-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.alpha.3.beta.4 nicotinic
receptor antagonist combination for treating
addiction disorders)
IT 50-36-2, Cocaine 54-11-5, Nicotine
300-62-9, Amphetamine 561-27-3, Heroin
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)
(.alpha.3.beta.4 nicotinic
receptor antagonist combination for treating
addiction disorders)
RN 50-36-2 HCAPLUS
CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R,2R,3S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 54-11-5 HCAPLUS
CN Pyridine, 3-[(2S)-1-methyl-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 300-62-9 HCAPLUS
CN Benzeneethanamine, .alpha.-methyl- (9CI) (CA INDEX NAME)



RN 561-27-3 HCAPLUS
CN Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-
(5.alpha.,6.alpha.)-, diacetate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **57-27-2**, **Morphine**, biological studies **64-31-3**,
Morphine sulfate **537-46-2**, **Methamphetamine**
28297-73-6, **Methamphetamine** sulfate
RL: PAC (Pharmacological activity); BIOL (Biological study)
(**.alpha.3.beta.4** nicotinic
receptor antagonist **combination** for treating
addiction disorders)
RN 57-27-2 HCAPLUS
CN Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-
(5.alpha.,6.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 64-31-3 HCAPLUS
CN Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-
(5.alpha.,6.alpha.)-, sulfate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9
CMF H2 O4 S



CM 2

CRN 57-27-2
CMF C17 H19 N O3

Absolute stereochemistry. Rotation (-).



RN 537-46-2 HCAPLUS
CN Benzeneethanamine, N,.alpha.-dimethyl-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 28297-73-6 HCAPLUS
CN Benzeneethanamine, N,.alpha.-dimethyl-, (.alpha.S)-, sulfate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9
CMF H2 O4 S



CM 2

CRN 537-46-2
CMF C10 H15 N

Absolute stereochemistry. Rotation (+).



IT **60-40-2**, **Mecamylamine** **125-69-9**, **Dextromethorphan** hydrobromide **125-71-3**, **Dextromethorphan** **125-73-5**, **Dextrorphan** **467-77-6**, **18-Methoxycoronaridine** **826-39-1**, **Mecamylamine** hydrochloride **34911-55-2**, **Bupropion** **266686-75-3** **266686-77-5** **444143-81-1** **444143-82-2**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**.alpha.3.beta.4** nicotinic receptor antagonist **combination** for treating **addiction** disorders)
RN 60-40-2 HCAPLUS
CN Bicyclo[2.2.1]heptan-2-amine, N,2,3,3-tetramethyl- (9CI) (CA INDEX NAME)



RN 125-69-9 HCAPLUS

CN Morphinan, 3-methoxy-17-methyl-, hydrobromide, (9.alpha.,13.alpha.,14.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HBr

RN 125-71-3 HCAPLUS
CN Morphinan, 3-methoxy-17-methyl-, (9.alpha.,13.alpha.,14.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 125-73-5 HCAPLUS
CN Morphinan-3-ol, 17-methyl-, (9.alpha.,13.alpha.,14.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 467-77-6 HCAPLUS
CN Ibogamine-18-carboxylic acid, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 826-39-1 HCAPLUS
CN Bicyclo[2.2.1]heptan-2-amine, N,2,3,3-tetramethyl-, hydrochloride (9CI) (CA INDEX NAME)



HCl

RN 34911-55-2 HCAPLUS
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)



RN 266686-75-3 HCAPLUS
CN Ibogamine-18-carboxylic acid, 21-methoxy-, methyl ester, monohydrochloride, (2.alpha.,4.alpha.,5.beta.,6.alpha.,18.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 266686-77-5 HCAPLUS
CN Ibogamine-18-carboxylic acid, 21-methoxy-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 444143-81-1 HCAPLUS
CN Morphinan, 3-methoxy-17-methyl-, (9.alpha.,13.alpha.,14.alpha.)-, mixt. with N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine (9CI) (CA INDEX NAME)

CM 1

CRN 125-71-3
CMF C18 H25 N O

Absolute stereochemistry.



CM 2

CRN 60-40-2
CMF C11 H21 N



RN 444143-82-2 HCAPLUS
CN Morphinan-3-ol, 17-methyl-, (9.alpha.,13.alpha.,14.alpha.)-, mixt. with N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine (9CI) (CA INDEX NAME)

CM 1

CRN 125-73-5
CMF C17 H23 N O

Absolute stereochemistry.



CM 2

CRN 60-40-2
CMF C11 H21 N



L105 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:211766 HCAPLUS
DN 137:134941
TI Antagonism of .**alpha.3.beta.4** nicotinic receptors as a strategy to reduce **opioid** and stimulant self-administration
AU Glick, Stanley D.; Maisonneuve, Isabelle M.; Kitchen, Barbara A.; Fleck, Mark W.
CS Albany Medical College (MC-136), Center for Neuropharmacology and Neuroscience, Albany, NY, 12208, USA
SO European Journal of Pharmacology (2002), 438(1-2), 99-105
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier Science B.V.
DT Journal
LA English
CC 1-11 (Pharmacology)
AB The iboga alkaloid **ibogaine** and the novel iboga alkaloid congener **18-methoxycoronaridine** are putative anti-**addictive** agents. Using patch-clamp methodol., the actions of **ibogaine** and **18-methoxycoronaridine** at various neurotransmitter receptor ion-channel subtypes were detd. Both **ibogaine** and **18-methoxycoronaridine** were antagonists at .**alpha.3.beta.4** nicotinic receptors and both agents were more potent at this site than at .alpha.4.beta.2 nicotinic receptors or at NMDA or 5-HT3 receptors; **18-methoxycoronaridine** was more selective in this regard than **ibogaine**. In studies of **morphine** and **methamphetamine** self-administration, the effects of low dose **combinations** of **18-methoxycoronaridine** with **mecamylamine** or **dextromethorphan** and of **mecamylamine** with **dextromethorphan** were assessed. **Mecamylamine** and **dextromethorphan** have also been shown to be antagonists at .**alpha.3.beta.4** nicotinic receptors. All three **drug combinations** decreased both **morphine** and **methamphetamine** self-administration at doses that were ineffective if administered alone. The data are consistent with the hypothesis that antagonism at .**alpha.3.beta.4** receptors is a potential mechanism to modulate **drug** seeking behavior. **18-Methoxycoronaridine** apparently has greater selectivity for this site than other agents and may be the first of a new class of synthetic agents acting via this novel mechanism to produce a broad spectrum of anti-**addictive** activity.
ST nicotinic receptor antagonism **opioid** self administration drug **abuse**
IT 5-HT receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(5-HT3; antagonism of .**alpha.3.beta.4** nicotinic receptors as a strategy to reduce **opioid** and stimulant self-administration)
IT Glutamate receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NMDA-binding; antagonism of .**alpha.3.beta.**

4 nicotinic receptors as a strategy to reduce **opioid** and stimulant self-administration)

IT **Drug dependence**
Drugs of abuse
(antagonism of .**alpha.3.beta.4** nicotinic receptors as a strategy to reduce **opioid** and stimulant self-administration)

IT **Nicotinic receptors**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonism of .**alpha.3.beta.4** nicotinic receptors as a strategy to reduce **opioid** and stimulant self-administration)

IT Behavior
(self-administration; antagonism of .**alpha.3** .**beta.4** nicotinic receptors as a strategy to reduce **opioid** and stimulant self-administration)

IT **57-27-2, Morphine**, biological studies **537-46-2, Methamphetamine**
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(antagonism of .**alpha.3.beta.4** nicotinic receptors as a strategy to reduce **opioid** and stimulant self-administration)

IT **60-40-2, Mecamylamine 83-74-9, Ibogaine 125-71-3, Dextromethorphan 467-77-6, 18-Methoxycoronaridine**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antagonism of .**alpha.3.beta.4** nicotinic receptors as a strategy to reduce **opioid** and stimulant self-administration)

RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Badio, B; Mol Pharmacol 1997, V51, P1 HCAPLUS
(2) Chen, K; Neuropharmacology 1996, V35, P423 HCAPLUS
(3) Ebert, B; Biochem Pharmacol 1998, V56, P553 HCAPLUS
(4) Flores, C; Mol Pharmacol 1992, V41, P31 HCAPLUS
(5) Fryer, J; J Pharmacol Exp Ther 1999, V288, P88 HCAPLUS
(6) Glick, S; Ann N Y Acad Sci 1998, V844, P214 HCAPLUS
(7) Glick, S; Ann N Y Acad Sci 2000, V914, P369 HCAPLUS
(8) Glick, S; Ann N Y Acad Sci 2000, V909, P88 HCAPLUS
(9) Glick, S; Brain Res 1996, V719, P29 HCAPLUS
(10) Glick, S; Eur J Pharmacol 1991, V195, P341 HCAPLUS
(11) Glick, S; Eur J Pharmacol 2001, V422, P87 HCAPLUS
(12) Glick, S; NeuroReport 2000, V11, P2013 HCAPLUS
(13) Hernandez, S; J Pharmacol Exp Ther 2000, V293, P962 HCAPLUS
(14) Jun, J; Pharmacol Biochem Behav 2000, V67, P405 HCAPLUS
(15) Klink, R; J Neurosci 2001, V21, P1452 HCAPLUS
(16) Koyuncuoglu, H; Int J Clin Pharmacol Ther 1990, V28, P147 MEDLINE
(17) Koyuncuoglu, H; Int J Clin Pharmacol Ther 1995, V33, P13 MEDLINE
(18) Levin, E; Soc Neurosci Abstr 2000, V26, P1821
(19) Mah, S; Brain Res 1998, V797, P173 HCAPLUS
(20) Maisonneuve, I; Eur J Pharmacol 1999, V383, P15 HCAPLUS
(21) Murray, T; Life Sci 1984, V34, P1899 HCAPLUS
(22) Nishikawa, T; Brain Res 1986, V373, P324 HCAPLUS
(23) Papke, R; J Pharmacol Exp Ther 2001, V297, P646 HCAPLUS
(24) Popik, P; J Pharmacol Exp Ther 1995, V275, P753 HCAPLUS
(25) Pulvirenti, L; Eur J Pharmacol 1997, V321, P279 HCAPLUS
(26) Quick, M; Neuropharmacology 1999, V38, P769 HCAPLUS
(27) Reid, M; Neuropsychopharmacology 1999, V20, P297 HCAPLUS
(28) Rezvani, A; Pharmacol Biochem Behav 1997, V58, P615 HCAPLUS
(29) Sweetnam, P; Psychopharmacology 1995, V118, P369 HCAPLUS
(30) Weeks, J; Methods in Psychobiology 1972, V2, P155

IT **57-27-2, Morphine**, biological studies **537-46-2**

, **Methamphetamine**
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(antagonism of **.alpha.3.beta.4**
nicotinic receptors as a strategy to reduce **opioid** and
stimulant self-administration)
RN 57-27-2 HCAPLUS
CN Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-
(5.alpha.,6.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 537-46-2 HCAPLUS
CN Benzeneethanamine, N,.alpha.-dimethyl-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **60-40-2, Mecamylamine 83-74-9,**
Ibogaine 125-71-3, Dextromethorphan
467-77-6, 18-Methoxycoronaridine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(antagonism of **.alpha.3.beta.4**
nicotinic receptors as a strategy to reduce **opioid** and
stimulant self-administration)
RN 60-40-2 HCAPLUS
CN Bicyclo[2.2.1]heptan-2-amine, N,2,3,3-tetramethyl- (9CI) (CA INDEX NAME)



RN 83-74-9 HCAPLUS
CN Ibogamine, 12-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 125-71-3 HCAPLUS
CN Morphinan, 3-methoxy-17-methyl-, (9.alpha.,13.alpha.,14.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 467-77-6 HCAPLUS
CN Ibogamine-18-carboxylic acid, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L105 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2003 ACS
AN **2001:545488** HCAPLUS
DN **135:117246**
TI Methods using a .mu. **opioid** antagonist, calcium channel blocker, and NMDA glutamate receptor modulator for the treatment of substance **abuse**
IN Shulman, Albert
PA Australia
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent

LA English
IC ICM A61K031-485
ICS A61K031-16; A61K031-277; A61K031-4422; A61K031-4418; A61K031-554; A61K031-4965; A61P025-30; A61P025-32; A61P025-34; A61P025-36
CC 1-11 (Pharmacology)
Section cross-reference(s): 4
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001052851	A1	20010726	WO 2001-AU60	20010122
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001026574	A5	20010731	AU 2001-26574	20010122
	EP 1250136	A1	20021023	EP 2001-901062	20010122
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NO 2002003482	A	20020919	NO 2002-3482	20020722
PRAI	GB 2000-1390	A	20000122		
	GB 2000-1647	A	20000126		
	AU 2000-2237	A	20001221		
	AU 2000-22370	A	20001221		
	WO 2001-AU60	W	20010122		

AB Methods are provided for therapy for **substance** (e.g. **alc**.) **addiction** which **comprise** the administration of a **combination** of (i) a .mu.-**opioid** receptor antagonist; (ii) a calcium channel blocker which is long-acting or in sustained-release form or which is nimodipine in rapid release form; and (iii) an NMDA glutamate receptor modulator. Also provided are **combinations**, kits and **compns**. useful therefor.

ST **substance abuse** treatment mu **opioid** antagonist **combination**; nimodipine calcium channel blocker **substance abuse** treatment; NMDA glutamate receptor modulator **substance abuse** treatment; **alc addiction combination** treatment

IT Glutamate receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(NMDA-binding; .mu. **opioid** antagonist, calcium channel blocker, and NMDA glutamate receptor modulator for treatment of substance **abuse**)

IT **Drugs of abuse**
(**abuse** of; .mu. **opioid** antagonist, calcium channel blocker, and NMDA glutamate receptor modulator for treatment of substance **abuse**)

IT Ion channel blockers
(calcium; .mu. **opioid** antagonist, calcium channel blocker, and NMDA glutamate receptor modulator for treatment of substance **abuse**)

IT Drug delivery systems
(oral; .mu. **opioid** antagonist, calcium channel blocker, and NMDA glutamate receptor modulator for treatment of substance **abuse**)

IT Paints
(paint solvent inhalants; .mu. **opioid** antagonist, calcium channel blocker, and NMDA glutamate receptor modulator for treatment of substance **abuse**)

IT Volatile substances
(solvents, inhalant; .mu. **opioid** antagonist, calcium channel blocker, and NMDA glutamate receptor modulator for treatment of substance **abuse**)
IT Drug delivery systems
(sustained-release; .mu. **opioid** antagonist, calcium channel blocker, and NMDA glutamate receptor modulator for treatment of substance **abuse**)
IT Solvents
(volatile, inhalant; .mu. **opioid** antagonist, calcium channel blocker, and NMDA glutamate receptor modulator for treatment of substance **abuse**)
IT **Opioids**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.kappa.-; .mu. **opioid** antagonist, calcium channel blocker, and NMDA glutamate receptor modulator for treatment of substance **abuse**)
IT **Alcoholism**
Cannabis
Drug delivery systems
Drug dependence
Drug interactions
Nicotinic antagonists
(.mu. **opioid** antagonist, calcium channel blocker, and NMDA glutamate receptor modulator for treatment of **substance abuse**)
IT **Opioids**
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(.mu. **opioid** antagonist, calcium channel blocker, and NMDA glutamate receptor modulator for treatment of substance **abuse**)
IT **Opioid** antagonists
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.mu.-**opioid**; .mu. **opioid** antagonist, calcium channel blocker, and NMDA glutamate receptor modulator for treatment of substance **abuse**)
IT **54-11-5, Nicotine 64-17-5, Ethanol,**
biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(.mu. **opioid** antagonist, calcium channel blocker, and NMDA glutamate receptor modulator for treatment of substance **abuse**)
IT 52-53-9, Verapamil **60-40-2, Mecamylamine**
83-74-9, Ibogaine 1003-51-6, HA966 1477-40-3
16590-41-3, Naltrexone 19982-08-2, Memantine 21829-25-4, Nifedipine
22609-73-0, Niludipine 23210-56-2, Ifenprodil **34911-55-2,**
Bupropion 39562-70-4, Nitrendipine 42399-41-7, Diltiazem
52468-60-7, Flunarizine 52485-79-7, Buprenorphine 55096-26-9,
Nalmefene 55985-32-5, Nicardipine 63675-72-9, Nisoldipine
66085-59-4, Nimodipine 68506-86-5, .gamma.-vinyl-GABA 71653-63-9,
Riodipine 72509-76-3, Felodipine 72803-02-2, Darodipine 75530-68-6,
Nilvadipine 75695-93-1, Isradipine 77086-21-6, Dizocilpine
77337-76-9, Acamprosate 77590-96-6, Flordipine 88150-42-9, Amlodipine
90729-41-2, Oxodipine 94739-29-4, Lemildipine 100828-16-8,
3-(2-Carboxypiperazin-4-yl)propyl-1-phosphonic acid 103890-78-4,
Lacidipine 113165-32-5, Niguldipine 119413-55-7, Elgodipine
119431-25-3, Eliprodil
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)
(.mu. **opioid** antagonist, calcium channel blocker, and NMDA glutamate receptor modulator for treatment of substance **abuse**)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Calcagnetti, D; Life Sciences 1995, V56(7), P475 HCAPLUS
(2) Lipha; EP 945133 A 1999 HCAPLUS
(3) Merck Sharp & Dohme Limited; WO 99/44610 A 1999 HCAPLUS
(4) Novoneuron, Inc; WO 99/11250 A 1999 HCAPLUS
(5) Terenius, L; Current Opinion in Chemical Biology 1998, V2(4), P541 HCAPLUS

IT **54-11-5, Nicotine 64-17-5, Ethanol,**
biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(.mu. **opioid** antagonist, calcium channel blocker, and NMDA glutamate receptor modulator for treatment of substance **abuse**)

RN 54-11-5 HCAPLUS
CN Pyridine, 3-[(2S)-1-methyl-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 64-17-5 HCAPLUS
CN Ethanol (9CI) (CA INDEX NAME)

H_3C-CH_2-OH

IT **60-40-2, Mecamylamine 83-74-9,**
Ibogaine 34911-55-2, Bupropion
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.mu. **opioid** antagonist, calcium channel blocker, and NMDA glutamate receptor modulator for treatment of substance **abuse**)

RN 60-40-2 HCAPLUS
CN Bicyclo[2.2.1]heptan-2-amine, N,2,3,3-tetramethyl- (9CI) (CA INDEX NAME)



RN 83-74-9 HCAPLUS
CN Ibogamine, 12-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 34911-55-2 HCAPLUS
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)



L105 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2003 ACS
AN 2000:373737 HCAPLUS
DN 133:99376
TI **Dextromethorphan** and its metabolite **dextrorphan** block **.alpha.3.beta.4** neuronal nicotinic receptors
AU Hernandez, Susan C.; Bertolino, Maria; Xiao, Yingxian; Pringle, Kenneth E.; Caruso, Frank S.; Kellar, Kenneth J.
CS Department of Pharmacology, Georgetown University School of Medicine, Washington, DC, USA
SO Journal of Pharmacology and Experimental Therapeutics (2000), 293(3), 962-967
CODEN: JPETAB; ISSN: 0022-3565
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
CC 1-9 (Pharmacology)
Section cross-reference(s): 13
AB **Dextromethorphan** (DM), a structural analog of **morphine** and codeine, has been widely used as a cough suppressant for more than 40 yr. DM is not itself a potent analgesic, but it has been reported to enhance analgesia produced by **morphine** and nonsteroidal anti-inflammatory **drugs**. Although DM is considered to be nonaddictive, it has been reported to reduce **morphine** tolerance in rats and to be useful in helping **addicted** subjects to **withdraw** from **heroin**. Here we studied the effects of DM on neuronal nicotinic receptors stably expressed in human embryonic kidney cells. Studies were carried out to examine the effects of DM on **nicotine**-stimulated whole cell currents and **nicotine** -stimulated 86Rb+ efflux. We found that both DM and its metabolite **dextrorphan** block nicotinic receptor function in a noncompetitive but reversible manner, suggesting that both **drugs** block the receptor channel. Consistent with blockade of the receptor channel, neither **drug** competed for the nicotinic agonist binding sites

labeled by [3H]epibatidine. Although DM is approx. 9-fold less potent than the widely used noncompetitive nicotinic antagonist **mecamylamine** in blocking nicotinic receptor function, the block by DM appears to reverse more slowly than that by **mecamylamine**. These data indicate that DM is a useful antagonist for studying nicotinic receptor function and suggest that it might prove to be a clin. useful neuronal nicotinic receptor antagonist, possibly helpful as an aid for helping people **addicted** to **nicotine** to refrain from **smoking**, as well as in other conditions where blockade of neuronal nicotinic receptors would be helpful.

ST **dextromethorphan dextrorphan** neuronal nicotinic receptor **nicotine addiction**

IT **Tobacco smoke**
(**dextromethorphan** and metabolite **dextrorphan** block **.alpha.3.beta.4** neuronal nicotinic receptors)

IT **Nicotinic receptors**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(**dextromethorphan** and metabolite **dextrorphan** block **.alpha.3.beta.4** neuronal nicotinic receptors)

IT Nerve
(neuron; **dextromethorphan** and metabolite **dextrorphan** block **.alpha.3.beta.4** neuronal nicotinic receptors)

IT **Drug dependence**
(to **nicotine**; **dextromethorphan** and metabolite **dextrorphan** block **.alpha.3.beta.4** neuronal nicotinic receptors)

IT **54-11-5, Nicotine**
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(**addiction**; **dextromethorphan** and metabolite **dextrorphan** block **.alpha.3.beta.4** neuronal nicotinic receptors)

IT **125-71-3, Dextromethorphan 125-73-5, Dextrorphan**
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**dextromethorphan** and metabolite **dextrorphan** block **.alpha.3.beta.4** neuronal nicotinic receptors)

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Amador, M; Synapse 1991, V7, P207 MEDLINE
(2) Bem, J; Drug Saf 1992, V7, P190 MEDLINE
(3) Briggs, C; Neuropharmacology 1996, V35, P407 HCAPLUS
(4) Capon, D; Clin Pharmacol Ther 1996, V60, P295 HCAPLUS
(5) Choi, D; Brain Res 1987, V403, P333 HCAPLUS
(6) Choi, D; J Pharmacol Exp Ther 1987, V242, P713 HCAPLUS
(7) Church, J; Eur J Pharmacol 1985, V111, P185 HCAPLUS
(8) Elliott, K; Pain 1994, V59, P361 HCAPLUS
(9) Halliwell, R; Br J Pharmacol 1989, V96, P480 HCAPLUS
(10) Hernandez, S; Soc Neurosci Abstr 1998, V24, P86
(11) Koyuncuoglu, H; Int J Clin Pharmacol Ther Toxicol 1990, V28, P147 MEDLINE
(12) Lukas, R; Anal Biochem 1988, V175, P212 HCAPLUS
(13) Mao, J; Pain 1996, V67, P361 HCAPLUS
(14) Maus, A; Mol Pharmacol 1998, V54, P779 HCAPLUS
(15) Price, D; Pain 1996, V68, P119 HCAPLUS
(16) Ramoa, A; J Pharmacol Exp Ther 1990, V254, P71 HCAPLUS
(17) Reisine, T; Goodman and Gilman's The Pharmacological Basis of Therapeutics 1996, P521
(18) Rose, J; Clin Pharmacol Ther 1994, V56, P86 HCAPLUS

(19) Rose, J; Exp Clin Psychopharmacol 1998, V6, P331 HCAPLUS
(20) Shoaib, M; Br J Pharmacol 1994, V111, P1073 HCAPLUS
(21) Shoaib, M; J Pharmacol 1992, V105, P514 HCAPLUS
(22) Xiao, Y; Mol Pharmacol 1998, V54, P322 HCAPLUS
(23) Yamamoto, H; Neurosci Lett 1992, V147, P97 HCAPLUS
(24) Zia, S; Res Commun Mol Pathol Pharmacol 1997, V97, P243 HCAPLUS

IT **54-11-5, Nicotine**
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(**addiction; dextromethorphan** and metabolite **dextrorphan** block **.alpha.3.beta.4** neuronal nicotinic receptors)
RN 54-11-5 HCAPLUS
CN Pyridine, 3-[(2S)-1-methyl-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **125-71-3, Dextromethorphan 125-73-5, Dextrorphan**
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**dextromethorphan** and metabolite **dextrorphan** block **.alpha.3.beta.4** neuronal nicotinic receptors)
RN 125-71-3 HCAPLUS
CN Morphinan, 3-methoxy-17-methyl-, (9.alpha.,13.alpha.,14.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 125-73-5 HCAPLUS
CN Morphinan-3-ol, 17-methyl-, (9.alpha.,13.alpha.,14.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> fil reg
FILE 'REGISTRY' ENTERED AT 16:44:50 ON 10 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 9 MAR 2003 HIGHEST RN 497220-90-3
DICTIONARY FILE UPDATES: 9 MAR 2003 HIGHEST RN 497220-90-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d ide can tot l106

L106 ANSWER 1 OF 21 REGISTRY COPYRIGHT 2003 ACS
RN **444143-82-2** REGISTRY
CN Morphinan-3-ol, 17-methyl-, (9.alpha.,13.alpha.,14.alpha.)-, mixt. with
N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C17 H23 N O . C11 H21 N
CI MXS
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 125-73-5
CMF C17 H23 N O

Absolute stereochemistry.



CM 2

CRN 60-40-2
CMF C11 H21 N



1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:119689

L106 ANSWER 2 OF 21 REGISTRY COPYRIGHT 2003 ACS
RN **444143-81-1** REGISTRY
CN Morphinan, 3-methoxy-17-methyl-, (9.alpha.,13.alpha.,14.alpha.)-, mixt. with N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H25 N O . C11 H21 N
CI MXS
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 125-71-3
CMF C18 H25 N O

Absolute stereochemistry.



CM 2

CRN 60-40-2
CMF C11 H21 N



1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:119689

L106 ANSWER 3 OF 21 REGISTRY COPYRIGHT 2003 ACS
RN **266686-77-5** REGISTRY
CN Ibogamine-18-carboxylic acid, 21-methoxy-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (-)-18-Methoxycoronaridine hydrochloride
FS STEREOSEARCH
MF C22 H28 N2 O3 . Cl H
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, CASREACT, DRUGUPDATES, TOXCENTER, USPATFULL
CRN (308123-60-6)

Absolute stereochemistry. Rotation (-).



● HCl

3 REFERENCES IN FILE CA (1962 TO DATE)
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:119689

REFERENCE 2: 135:318602

REFERENCE 3: 132:322018

L106 ANSWER 4 OF 21 REGISTRY COPYRIGHT 2003 ACS
RN **266686-75-3** REGISTRY
CN Ibogamine-18-carboxylic acid, 21-methoxy-, methyl ester, monohydrochloride, (2.alpha.,4.alpha.,5.beta.,6.alpha.,18.beta.)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (+)-18-Methoxycoronaridine hydrochloride
FS STEREOSEARCH
MF C22 H28 N2 O3 . Cl H
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL
CRN (308123-59-3)

Absolute stereochemistry. Rotation (+).



HCl

3 REFERENCES IN FILE CA (1962 TO DATE)
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:119689

REFERENCE 2: 135:318602

REFERENCE 3: 132:322018

L106 ANSWER 5 OF 21 REGISTRY COPYRIGHT 2003 ACS
RN **34911-55-2** REGISTRY
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, (.+-.)-
OTHER NAMES:
CN (.+-.)-Bupropion
CN .alpha.-(tert-Butylamino)-m-chloropropiophenone
CN Amfebutamon
CN Amfebutamone
CN Bupropion
DR 34841-39-9
MF C13 H18 Cl N O
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, PHAR, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

478 REFERENCES IN FILE CA (1962 TO DATE)
9 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
482 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:147554

REFERENCE 2: 138:147499

REFERENCE 3: 138:130984

REFERENCE 4: 138:130913

REFERENCE 5: 138:117464

REFERENCE 6: 138:101071

REFERENCE 7: 138:66716

REFERENCE 8: 138:66689

REFERENCE 9: 138:61356

REFERENCE 10: 138:61315

L106 ANSWER 6 OF 21 REGISTRY COPYRIGHT 2003 ACS
RN **28297-73-6** REGISTRY
CN Benzeneethanamine, N,.alpha.-dimethyl-, (.alpha.S)-, sulfate (2:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzeneethanamine, N,.alpha.-dimethyl-, (S)-, sulfate (2:1)
CN Phenethylamine, N,.alpha.-dimethyl-, sulfate (2:1), (+)- (8CI)
OTHER NAMES:
CN (+)-Methamphetamine sulfate
CN Methamphetamine sulfate
FS STEREOSEARCH
MF C10 H15 N . 1/2 H2 O4 S
LC STN Files: BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, EMBASE, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

CM 1

CRN 7664-93-9
CMF H2 O4 S



CM 2

CRN 537-46-2
CMF C10 H15 N

Absolute stereochemistry. Rotation (+).



7 REFERENCES IN FILE CA (1962 TO DATE)
7 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:119689

REFERENCE 2: 93:215173

REFERENCE 3: 86:183262

REFERENCE 4: 86:50646

REFERENCE 5: 84:173762

REFERENCE 6: 77:122141

REFERENCE 7: 72:77108

L106 ANSWER 7 OF 21 REGISTRY COPYRIGHT 2003 ACS

RN **826-39-1** REGISTRY
CN Bicyclo[2.2.1]heptan-2-amine, N,2,3,3-tetramethyl-, hydrochloride (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Norbornanamine, N,2,3,3-tetramethyl-, hydrochloride (8CI)
OTHER NAMES:
CN Inversine
CN Mecamylamine chloride
CN Mecamylamine hydrochloride
CN Mevasin
CN Mevasine
CN N,2,3,3-Tetramethyl-2-norbornanamine hydrochloride
MF C11 H21 N . Cl H
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DIOGENES, EMBASE, HODOC*, IPA, MRCK*, PROMT, RTECS*, TOXCENTER, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (60-40-2)



HCl

158 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
158 REFERENCES IN FILE CAPLUS (1962 TO DATE)
10 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:210809

REFERENCE 2: 137:119689

REFERENCE 3: 136:156476

REFERENCE 4: 136:156475

REFERENCE 5: 136:11105

REFERENCE 6: 133:242669

REFERENCE 7: 132:293042

REFERENCE 8: 131:633

REFERENCE 9: 130:252506

REFERENCE 10: 130:10535

L106 ANSWER 8 OF 21 REGISTRY COPYRIGHT 2003 ACS

RN **561-27-3** REGISTRY
CN Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-
(5.alpha.,6.alpha.)-, diacetate (ester) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Morphinan-3,6.alpha.-diol, 7,8-didehydro-4,5.alpha.-epoxy-17-methyl-,
diacetate (ester) (8CI)
OTHER NAMES:
CN 3,6-Diacetylmorphine
CN 3,6-O-Diacetylmorphine
CN Acetomorphin
CN Acetomorphine
CN China white
CN Diacetylmorphine
CN Diamorphine
CN Diaphorm
CN Eclorion
CN Heroin
CN Morphacetin
CN Preza
FS STEREOSEARCH
DR 2078-90-2
MF C21 H23 N O5
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*, DRUGU, EMBASE, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2160 REFERENCES IN FILE CA (1962 TO DATE)
36 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2165 REFERENCES IN FILE CAPLUS (1962 TO DATE)
18 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:149691

REFERENCE 2: 138:132331

REFERENCE 3: 138:132323

REFERENCE 4: 138:130994

REFERENCE 5: 138:130993

REFERENCE 6: 138:130957

REFERENCE 7: 138:130455

REFERENCE 8: 138:122643

REFERENCE 9: 138:118594

REFERENCE 10: 138:117517

L106 ANSWER 9 OF 21 REGISTRY COPYRIGHT 2003 ACS
RN **537-46-2** REGISTRY
CN Benzeneethanamine, N,.alpha.-dimethyl-, (.alpha.S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzeneethanamine, N,.alpha.-dimethyl-, (S)-
CN Phenethylamine, N,.alpha.-dimethyl-, (S)-(+)- (8CI)
OTHER NAMES:
CN (+)-(S)-Deoxyephedrine
CN (+)-2-(N-Methylamino)-1-phenylpropane
CN (+)-Methamphetamine
CN (+)-Methylamphetamine
CN (+)-N,.alpha.-Dimethyl-.beta.-phenylethylamine
CN (+)-N-Methylamphetamine
CN (S)-(+)-Deoxyephedrine
CN (S)-(+)-Methamphetamine
CN (S)-Methamphetamine
CN (S)-Methylamphetamine
CN 2S-(+)-Methamphetamine
CN d-(S)-Methamphetamine
CN d-Deoxyephedrine
CN d-Desoxyephedrine
CN d-Methamphetamine
CN d-Methylamphetamine
CN d-N,.alpha.-Dimethylphenethylamine
CN d-N-Methylamphetamine
CN d-Phenylisopropylmethylamine
CN L-Methamphetamine
CN Metamfetamine
CN Metamphetamine
CN Methamphetamine
CN Methyl-.beta.-phenylisopropylamine
CN Methylamphetamine
CN N-Methyl-1-phenyl-2-propanamine
CN N-Methylamphetamine
CN Norodin
FS STEREOSEARCH
DR 139-47-9, 1690-86-4, 14611-50-8, 45952-89-4
MF C10 H15 N
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3409 REFERENCES IN FILE CA (1962 TO DATE)
79 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3422 REFERENCES IN FILE CAPLUS (1962 TO DATE)
19 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:148798

REFERENCE 2: 138:147614

REFERENCE 3: 138:147591

REFERENCE 4: 138:147588

REFERENCE 5: 138:147587

REFERENCE 6: 138:147580

REFERENCE 7: 138:147577

REFERENCE 8: 138:147574

REFERENCE 9: 138:147573

REFERENCE 10: 138:147552

L106 ANSWER 10 OF 21 REGISTRY COPYRIGHT 2003 ACS
RN **467-77-6** REGISTRY
CN Ibogamine-18-carboxylic acid, methyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 6,9-Methano-5H-pyrido[1',2':1,2]azepino[4,5-b]indole, ibogamine-18-carboxylic acid deriv.
CN Coronaridine (6CI, 7CI, 8CI)
OTHER NAMES:
CN (-)-Coronaridine
CN Coronaridin
FS STEREOSEARCH
DR 53368-34-6, 53777-64-3
MF C21 H26 N2 O2
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMLIST, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, NAPRALERT, SPECINFO, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

189 REFERENCES IN FILE CA (1962 TO DATE)
189 REFERENCES IN FILE CAPLUS (1962 TO DATE)
15 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:229149

REFERENCE 2: 137:134941

REFERENCE 3: 137:119689

REFERENCE 4: 137:44252

REFERENCE 5: 137:17724

REFERENCE 6: 136:111971

REFERENCE 7: 136:99153

REFERENCE 8: 135:339094

REFERENCE 9: 135:221260

REFERENCE 10: 135:164699

L106 ANSWER 11 OF 21 REGISTRY COPYRIGHT 2003 ACS
RN **300-62-9** REGISTRY
CN Benzeneethanamine, .alpha.-methyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzeneethanamine, .alpha.-methyl-, (.+-.)-
CN Phenethylamine, .alpha.-methyl-, (.+-.)- (8CI)
OTHER NAMES:
CN (.+-.)-.alpha.-Methylphenethylamine
CN (.+-.)-.alpha.-Methylphenylethylamine
CN (.+-.)-.beta.-Phenylisopropylamine
CN (.+-.)-1-Phenyl-2-aminopropane
CN (.+-.)-Desoxynorephedrine
CN (.+-.)-Phenylisopropylamine
CN .alpha.-Methyl-.beta.-phenylethylamine
CN .alpha.-Methylbenzeneethanamine
CN .alpha.-Methylphenethylamine
CN .alpha.-Methylphenylethylamine
CN .beta.-Aminopropylbenzene
CN .beta.-Phenylisopropylamine
CN 1-Benzylethylamine
CN 1-Methyl-2-phenylethylamine
CN 1-Phenyl-2-aminopropane

CN 1-Phenyl-2-propanamine
CN 1-Phenyl-2-propylamine
CN 2-Amino-1-phenylpropane
CN 3-Phenyl-2-propylamine
CN Actedron
CN Adderall
CN Adderall XR
CN Adipan
CN Allodene
CN Amfetamine
CN Amphetamine
CN Anorexine
CN Benzebar
CN Benzedrine
CN Benzolone
CN Desoxynorephedrine
CN dl-.alpha.-Methylphenethylamine
CN Elastonon
CN Fenopromin
CN Finam
CN Isoamyne
CN Isomyn
CN Mecodrin
CN Norephedrane
CN Novydrine
CN Obesin
CN Obesine
CN Oktedrin
CN Ortedrine
CN Percomon
CN Phenamine
CN Phenedrine
CN Profamina
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
FS 3D CONCORD
DR 60-15-1, 17108-96-2, 96332-84-2
MF C9 H13 N
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHARMASEARCH, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6575 REFERENCES IN FILE CA (1962 TO DATE)
461 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
6590 REFERENCES IN FILE CAPLUS (1962 TO DATE)
5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:153500

REFERENCE 2: 138:153411

REFERENCE 3: 138:150817

REFERENCE 4: 138:148885

REFERENCE 5: 138:148798

REFERENCE 6: 138:147755

REFERENCE 7: 138:147720

REFERENCE 8: 138:147572

REFERENCE 9: 138:147518

REFERENCE 10: 138:146984

L106 ANSWER 12 OF 21 REGISTRY COPYRIGHT 2003 ACS
RN **125-73-5** REGISTRY
CN Morphinan-3-ol, 17-methyl-, (9.alpha.,13.alpha.,14.alpha.)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 9.alpha.,13.alpha.,14.alpha.-Morphinan-3-ol, 17-methyl- (8CI)
OTHER NAMES:
CN (+)-3-Hydroxy-N-methylmorphinan
CN (+)-Dromoran
CN (+)-N-Methylmorphinan-3-ol
CN d-Levorphanol
CN dextro-Dromoran
CN Dextrorphan
CN O-Demethyldextromethorphan
CN Ro 1-6794
FS STEREOSEARCH
MF C17 H23 N O
CI COM
LC STN Files: ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

587 REFERENCES IN FILE CA (1962 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
587 REFERENCES IN FILE CAPLUS (1962 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:100318

REFERENCE 2: 138:66586

REFERENCE 3: 137:304240

REFERENCE 4: 137:257212

REFERENCE 5: 137:242132

REFERENCE 6: 137:227829

REFERENCE 7: 137:226632

REFERENCE 8: 137:226631

REFERENCE 9: 137:226630

REFERENCE 10: 137:119689

L106 ANSWER 13 OF 21 REGISTRY COPYRIGHT 2003 ACS
RN **125-71-3** REGISTRY
CN Morphinan, 3-methoxy-17-methyl-, (9.alpha.,13.alpha.,14.alpha.)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 9.alpha.,13.alpha.,14.alpha.-Morphinan, 3-methoxy-17-methyl- (8CI)
OTHER NAMES:
CN (+)-3-Methoxy-17-methylmorphinan
CN 14: PN: WO02073205 FIGURE: 8 claimed sequence
CN Ba 2666
CN d-Methorphan
CN DEX
CN Dextromethorphan
CN Nodex
FS STEREOSEARCH
DR 18046-32-7, 32062-10-5
MF C18 H25 N O
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, NIOSHTIC, PHAR, PROMT, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1239 REFERENCES IN FILE CA (1962 TO DATE)
30 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1241 REFERENCES IN FILE CAPLUS (1962 TO DATE)
4 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:131062

REFERENCE 2: 138:127069

REFERENCE 3: 138:121374

REFERENCE 4: 138:117565

REFERENCE 5: 138:117244

REFERENCE 6: 138:112443

REFERENCE 7: 138:100318

REFERENCE 8: 138:95638

REFERENCE 9: 138:83227

REFERENCE 10: 138:83226

L106 ANSWER 14 OF 21 REGISTRY COPYRIGHT 2003 ACS
RN **125-69-9** REGISTRY
CN Morphinan, 3-methoxy-17-methyl-, hydrobromide, (9.alpha.,13.alpha.,14.alpha.)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 9.alpha.,13.alpha.,14.alpha.-Morphinan, 3-methoxy-17-methyl-, hydrobromide (8CI)
OTHER NAMES:
CN Antussan
CN d-3-Methoxy-N-methylmorphinan hydrobromide
CN d-Methorphan hydrobromide
CN Delsym
CN Demorphan
CN Demorphine
CN Dextromethorphan bromide
CN Dextromethorphan hydrobromide
CN Dormetan
CN Dormethan
CN Medicon
CN Methorate hydrobromide
CN Metrorat

CN Ro 1-5470
CN Romilar
CN Tusilan
CN Tussade
FS STEREOSEARCH
DR 18651-95-1
MF C18 H25 N O . Br H
CI COM
LC STN Files: ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DIOGENES, EMBASE, IFICDB, IFIPAT, IFIUDB, MRCK*, MSDS-OHS, PHAR, PHARMASEARCH, PROMT, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (125-71-3)

Absolute stereochemistry.



● HBr

334 REFERENCES IN FILE CA (1962 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
336 REFERENCES IN FILE CAPLUS (1962 TO DATE)
7 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:158841

REFERENCE 2: 138:19521

REFERENCE 3: 138:8344

REFERENCE 4: 137:375291

REFERENCE 5: 137:329458

REFERENCE 6: 137:299959

REFERENCE 7: 137:175098

REFERENCE 8: 137:119689

REFERENCE 9: 137:68208

REFERENCE 10: 137:68189

L106 ANSWER 15 OF 21 REGISTRY COPYRIGHT 2003 ACS
RN **83-74-9** REGISTRY

CN Ibogamine, 12-methoxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 6,9-Methano-5H-pyrido[1',2':1,2]azepino[4,5-b]indole, ibogamine deriv..
CN Ibogaine (7CI, 8CI)
OTHER NAMES:
CN (-)-Ibogaine
CN Ibogain
FS STEREOSEARCH
DR 17378-46-0
MF C20 H26 N2 O
CI COM
LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DRUGNL, DRUGU, DRUGUPDATES, EMBASE, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT, PROMT, RTECS*, SPECINFO, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

331 REFERENCES IN FILE CA (1962 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
331 REFERENCES IN FILE CAPLUS (1962 TO DATE)
22 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:130452

REFERENCE 2: 137:315860

REFERENCE 3: 137:163719

REFERENCE 4: 137:150063

REFERENCE 5: 137:134941

REFERENCE 6: 137:83652

REFERENCE 7: 137:17724

REFERENCE 8: 136:363873

REFERENCE 9: 136:111979

REFERENCE 10: 136:111978

L106 ANSWER 16 OF 21 REGISTRY COPYRIGHT 2003 ACS
RN **64-31-3** REGISTRY
CN Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-
(5.alpha.,6.alpha.)-, sulfate (2:1) (salt) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Morphinan-3,6.alpha.-diol, 7,8-didehydro-4,5.alpha.-epoxy-17-methyl-,
sulfate (2:1) (salt) (8CI)
OTHER NAMES:
CN Avinza
CN Capros
CN Duramorph
CN Kapanol
CN l-Morphine sulfate
CN Morphelan
CN Morphine sulfate
CN Morphine sulphate
CN Moscontin
CN MST
CN MST Continus
CN NIH 0001
CN NIH 10753
CN Oblioser
CN Oramorph
CN Relipain
CN Roxanol
CN Skenan
FS STEREOSEARCH
DR 1095-53-0, 178935-96-1
MF C17 H19 N O3 . 1/2 H2 O4 S
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSNB, DIOGENES, EMBASE, HSDB*, MRCK*, MSDS-OHS, NIOSHTIC, PHAR, PHARMASEARCH, PIRA, PROMT, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

CM 1

CRN 7664-93-9
CMF H2 O4 S



CM 2

CRN 57-27-2
CMF C17 H19 N O3

Absolute stereochemistry. Rotation (-).



2328 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2329 REFERENCES IN FILE CAPLUS (1962 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:147161

REFERENCE 2: 138:137525

REFERENCE 3: 138:132324

REFERENCE 4: 138:130939

REFERENCE 5: 138:100838

REFERENCE 6: 138:49760

REFERENCE 7: 138:49341

REFERENCE 8: 138:33239

REFERENCE 9: 138:11332

REFERENCE 10: 137:389151

L106 ANSWER 17 OF 21 REGISTRY COPYRIGHT 2003 ACS
RN **64-17-5** REGISTRY
CN Ethanol (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Ethyl alcohol (6CI, 7CI, 8CI)
OTHER NAMES:
CN 100C.NPA
CN AHD 2000
CN Alcare Hand Degermer
CN Alcohol
CN Alcohol anhydrous
CN Algrain
CN Anhydrol
CN Anhydrol PM 4085
CN Desinfektol EL
CN Duplicating Fluid 100C.NPA
CN Esumiru WK 88
CN Ethicap
CN Ethyl hydrate
CN Ethyl hydroxide
CN Hinetoless
CN IMS 99
CN Jaysol
CN Jaysol S

CN Lux
CN Methylcarbinol
CN Molasses alcohol
CN Potato alcohol
CN SDA 3A
CN SDA 40-2
CN SY Fresh M
CN Synasol
CN Tecsol
CN Tecsol C
FS 3D CONCORD
DR 8000-16-6, 8024-45-1, 121182-78-3
MF C2 H6 O
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PHARMASEARCH, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, TULSA, ULIDAT, USAN, USPAT2, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

144662 REFERENCES IN FILE CA (1962 TO DATE)
1120 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
144645 REFERENCES IN FILE CAPLUS (1962 TO DATE)
11 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:162713

REFERENCE 2: 138:162704

REFERENCE 3: 138:162703

REFERENCE 4: 138:162687

REFERENCE 5: 138:162681

REFERENCE 6: 138:162573

REFERENCE 7: 138:162325

REFERENCE 8: 138:162324

REFERENCE 9: 138:162323

REFERENCE 10: 138:162314

L106 ANSWER 18 OF 21 REGISTRY COPYRIGHT 2003 ACS
RN **60-40-2** REGISTRY
CN Bicyclo[2.2.1]heptan-2-amine, N,2,3,3-tetramethyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Norbornanamine, N,2,3,3-tetramethyl- (8CI)

OTHER NAMES:
CN 2-(Methylamino)-2,3,3-trimethylnorborane
CN 2-(Methylamino)isocamphane
CN 3-(Methylamino)-2,2,3-trimethylbicyclo[2.2.1]heptane
CN 3-(Methylamino)isocamphane
CN Mecamine
CN Mecamylamine
CN N,2,3,3-Tetramethyl-2-norbornanamine
CN N,2,3,3-Tetramethyl-2-norcamphanamine
CN N-Methyl-2-isocamphanamine
CN Revertina
FS 3D CONCORD
MF C11 H21 N
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NIOSHTIC, PHAR, PROMT, RTECS*, SPECINFO, TOXCENTER, USAN, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

616 REFERENCES IN FILE CA (1962 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
616 REFERENCES IN FILE CAPLUS (1962 TO DATE)
22 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:117050

REFERENCE 2: 138:66592

REFERENCE 3: 138:66514

REFERENCE 4: 138:540

REFERENCE 5: 137:362410

REFERENCE 6: 137:320180

REFERENCE 7: 137:304675

REFERENCE 8: 137:257857

REFERENCE 9: 137:210824

REFERENCE 10: 137:210792

L106 ANSWER 19 OF 21 REGISTRY COPYRIGHT 2003 ACS

RN **57-27-2** REGISTRY
CN Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-
(5.alpha.,6.alpha.)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Morphinan-3,6.alpha.-diol, 7,8-didehydro-4,5.alpha.-epoxy-17-methyl- (8CI)
OTHER NAMES:
CN (-)-Morphine
CN Dulcontin
CN Duromorph
CN l-Morphine
CN Meconium
CN Morphia
CN Morphin
CN Morphina
CN Morphine
CN Morphinism
CN Morphinum
CN Morphium
CN MS Contin
CN Nepenthe
CN Ospalivina
FS STEREOSEARCH
DR 8053-16-5, 85201-37-2, 47106-99-0
MF C17 H19 N O3
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR, PHARMASEARCH, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

20068 REFERENCES IN FILE CA (1962 TO DATE)
241 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
20095 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:158859

REFERENCE 2: 138:149691

REFERENCE 3: 138:148048

REFERENCE 4: 138:147677

REFERENCE 5: 138:147610

REFERENCE 6: 138:147590

REFERENCE 7: 138:147568

REFERENCE 8: 138:147550

REFERENCE 9: 138:147531

REFERENCE 10: 138:147171

L106 ANSWER 20 OF 21 REGISTRY COPYRIGHT 2003 ACS
RN **54-11-5** REGISTRY
CN Pyridine, 3-[(2S)-1-methyl-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Nicotine (8CI)
CN Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)-
OTHER NAMES:
CN (-)-.beta.-Pyridyl-.alpha.-N-methylpyrrolidine
CN (-)-3-(1-Methyl-2-pyrrolidyl)pyridine
CN (-)-Nicotine
CN (S)-(-)-Nicotine
CN (S)-3-(1-Methyl-2-pyrrolidinyl)pyridine
CN (S)-Nicotine
CN Flux Maag
CN Habitrol
CN L-Nicotine
CN l-Nicotine
CN Nicabate
CN Nicoderm
CN Nicolan
CN Niconil
CN Nicopatch
CN Nicorette
CN Nicotell TTS
CN Nicotin
CN Nicotinell
CN Tabazur
CN XL All Insecticide
FS STEREOSEARCH
DR 13890-81-8, 13890-82-9, 6912-85-2, 551-13-3, 16760-37-5
MF C10 H14 N2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DRUGNL, DRUGU, DRUGUPDATES, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PHAR, PHARMASEARCH, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, TULSA, ULIDAT, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12435 REFERENCES IN FILE CA (1962 TO DATE)
232 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
12448 REFERENCES IN FILE CAPLUS (1962 TO DATE)
3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:157812

REFERENCE 2: 138:153704

REFERENCE 3: 138:151488

REFERENCE 4: 138:148949

REFERENCE 5: 138:148931

REFERENCE 6: 138:148758

REFERENCE 7: 138:148039

REFERENCE 8: 138:147617

REFERENCE 9: 138:147592

REFERENCE 10: 138:147584

L106 ANSWER 21 OF 21 REGISTRY COPYRIGHT 2003 ACS
RN **50-36-2** REGISTRY
CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R,2R,3S,5S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1.alpha.H,5.alpha.H-Tropane-2.beta.-carboxylic acid, 3.beta.-hydroxy-, methyl ester, benzoate (ester) (8CI)
CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, [1R-(exo,exo)]-
OTHER NAMES:
CN (-)-Cocaine
CN (R)-Cocaine
CN 2.beta.-Carbomethoxy-3.beta.-(benzoyloxy)tropane
CN 3.beta.-Hydroxy-2.beta.-tropanecarboxylic acid methyl ester benzoate (ester)
CN Benzoylmethylecgonine
CN Cocain
CN Cocaine
CN Ecgonine methyl ester benzoate (ester)
CN L-Cocaine
CN l-Cocaine
CN Neurocaine
FS STEREOSEARCH
DR 60269-50-3
MF C17 H21 N O4
CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

9786 REFERENCES IN FILE CA (1962 TO DATE)
262 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
9803 REFERENCES IN FILE CAPLUS (1962 TO DATE)
4 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:148778

REFERENCE 2: 138:147755

REFERENCE 3: 138:147596

REFERENCE 4: 138:147591

REFERENCE 5: 138:147581

REFERENCE 6: 138:147575

REFERENCE 7: 138:147534

REFERENCE 8: 138:147523

REFERENCE 9: 138:147522

REFERENCE 10: 138:147521

=> fil medline
FILE 'MEDLINE' ENTERED AT 17:01:04 ON 10 MAR 2003

FILE LAST UPDATED: 8 MAR 2003 (20030308/UP). FILE COVERS 1958 TO DATE.

On June 9, 2002, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2003 vocabulary. See http://www.nlm.nih.gov/mesh/summ2003.html for a description on changes.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all tot

L135 ANSWER 1 OF 2 MEDLINE
AN 2002396133 MEDLINE
DN 22140091 PubMed ID: 12144940
TI Modulation of nicotine self-administration in rats by combination therapy with agents blocking **alpha 3 beta 4 nicotinic receptors.**
AU Glick Stanley D; Maisonneuve Isabelle M; Kitchen Barbara A
CS Center for Neuropharmacology and Neuroscience, Albany Medical College (MC-136), 47 New Scotland Avenue, Albany, NY 12208, USA.. glicks@mail.amc.edu
NC DA 03817 (NIDA)
SO EUROPEAN JOURNAL OF PHARMACOLOGY, (2002 Jul 19) 448 (2-3) 185-91. Journal code: 1254354. ISSN: 0014-2999.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200302
ED Entered STN: 20020730
Last Updated on STN: 20030214
Entered Medline: 20030212
AB **18-Methoxycoronaridine**, a novel iboga alkaloid congener that decreases drug self-administration in several animal models, may be a potential treatment for multiple forms of drug abuse. In previous work, **18-methoxycoronaridine** was found to be a somewhat selective antagonist at **alpha3beta4 nicotinic receptors**; and low dose combinations of **18-methoxycoronaridine** with other drugs known to have the same action (e.g., **mecamylamine, dextromethorphan**) decreased both morphine and methamphetamine self-administration in rats at doses that were ineffective if administered alone. In the present study, similar drug combinations (but including **bupropion** as well) were found to decrease nicotine self-administration in rats. The data further support the hypothesis that diencephalic pathways having high densities of **alpha3beta4 nicotinic receptors** modulate mesocorticolimbic pathways more directly involved in drug reinforcement. Antagonists of **alpha3beta4 nicotinic receptors** may represent a totally novel approach to treating polydrug abuse. Copyright 2002 Elsevier Science B.V.
CT Check Tags: Animal; Female; Support, U.S. Gov't, P.H.S.
Dose-Response Relationship, Drug
Drug Therapy, Combination
*Nicotine: PD, pharmacology
***Nicotinic Antagonists: PD, pharmacology**
Rats
Rats, Long-Evans
***Receptors, Nicotinic: PH, physiology**
Self Administration: PX, psychology
RN 54-11-5 (Nicotine)
CN 0 (Nicotinic Antagonists); 0 (Receptors, Nicotinic); 0 (**nicotinic receptor alpha3beta4**)

L135 ANSWER 2 OF 2 MEDLINE
AN 2002174549 MEDLINE
DN 21904155 PubMed ID: 11906717
TI Antagonism of **alpha 3 beta 4 nicotinic receptors** as a strategy to reduce opioid and

stimulant self-administration.

AU Glick Stanley D; Maisonneuve Isabelle M; Kitchen Barbara A; Fleck Mark W
CS Center for Neuropharmacology and Neuroscience, Albany Medical College (MC-136), 47 New Scotland Avenue, Albany, NY 12208, USA..
glicks@mail.amc.edu

NC DA 03817 (NIDA)
SO EUROPEAN JOURNAL OF PHARMACOLOGY, (2002 Mar 1) 438 (1-2) 99-105.
Journal code: 1254354. ISSN: 0014-2999.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200205
ED Entered STN: 20020322
Last Updated on STN: 20020602
Entered Medline: 20020531

AB The iboga alkaloid **ibogaine** and the novel iboga alkaloid congener **18-methoxycoronaridine** are putative anti-addictive agents. Using patch-clamp methodology, the actions of **ibogaine** and **18-methoxycoronaridine** at various neurotransmitter receptor ion-channel subtypes were determined. Both **ibogaine** and **18-methoxycoronaridine** were antagonists at **alpha 3 beta 4 nicotinic receptors** and both agents were more potent at this site than at alpha 4 beta 2 **nicotinic receptors** or at NMDA or 5-HT(3) receptors; **18-methoxycoronaridine** was more selective in this regard than **ibogaine**. In studies of morphine and methamphetamine self-administration, the effects of low dose combinations of **18-methoxycoronaridine** with **mecamylamine** or **dextromethorphan** and of **mecamylamine** with **dextromethorphan** were assessed. **Mecamylamine** and **dextromethorphan** have also been shown to be antagonists at **alpha 3 beta 4 nicotinic receptors**. All three drug combinations decreased both morphine and methamphetamine self-administration at doses that were ineffective if administered alone. The data are consistent with the hypothesis that antagonism at **alpha 3 beta 4** receptors is a potential mechanism to modulate drug seeking behavior. **18-Methoxycoronaridine** apparently has greater selectivity for this site than other agents and may be the first of a new class of synthetic agents acting via this novel mechanism to produce a broad spectrum of anti-addictive activity.

CT Check Tags: Animal; Female; Human; Support, U.S. Gov't, P.H.S.
Acetylcholine: PD, pharmacology
Cell Line
Dose-Response Relationship, Drug
Excitatory Amino Acid Antagonists: PD, pharmacology
Gene Expression
***Ibogaine: AA, analogs & derivatives**
Ibogaine: PD, pharmacology
Membrane Potentials: DE, drug effects
*Narcotics: AD, administration & dosage
Rats
Rats, Long-Evans
Receptors, N-Methyl-D-Aspartate: AI, antagonists & inhibitors
Receptors, N-Methyl-D-Aspartate: PH, physiology
***Receptors, Nicotinic: DE, drug effects**
Receptors, Nicotinic: GE, genetics
Receptors, Nicotinic: PH, physiology
Receptors, Serotonin: DE, drug effects
Receptors, Serotonin: PH, physiology
Self Administration
RN 51-84-3 (Acetylcholine); **83-74-9 (Ibogaine)**

CN 0 (**18-methoxycoronaridine**); 0 (Excitatory Amino Acid Antagonists); 0 (Narcotics); 0 (Receptors, N-Methyl-D-Aspartate); 0 (Receptors, Nicotinic); 0 (Receptors, Serotonin); 0 (serotonin 3 receptor)

=> fil wpix
FILE 'WPIX' ENTERED AT 17:07:42 ON 10 MAR 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE LAST UPDATED: 7 MAR 2003 <20030307/UP>
MOST RECENT DERWENT UPDATE: 200316 <200316/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> SLART (Simultaneous Left and Right Truncation) is now available in the /ABEX field. An additional search field /BIX is also provided which comprises both /BI and /ABEX <<<

>>> PATENT IMAGES AVAILABLE FOR PRINT AND DISPLAY <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE http://www.derwent.com/dwpi/updates/dwpicov/index.html <<<

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER GUIDES, PLEASE VISIT:
http://www.derwent.com/userguides/dwpi_guide.html <<<

=> d all abeq tech abex tot

L156 ANSWER 1 OF 5 WPIX (C) 2003 THOMSON DERWENT
AN 2002-618941 [66] WPIX
DNC C2002-174706
TI Treating addiction disorder, e.g. nicotine addiction, comprises administering first and second alpha-3 beta-4 nicotinic receptor antagonist, where the first and second antagonists are different.
DC B05
IN GLICK, S D; MAISONNEUVE, I M
PA (GLIC-I) GLICK S D; (MAIS-I) MAISONNEUVE I M; (ALBA-N) ALBANY MEDICAL COLLEGE
CYC 100
PI US 2002103109 A1 20020801 (200266)* 17p A61K031-00
WO 2002060425 A1 20020808 (200266) EN A61K031-00
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW
ADT US 2002103109 A1 Provisional US 2001-264742P 20010129, US 2002-51770 20020118; WO 2002060425 A1 WO 2002-US2547 20020129
PRAI US 2001-264742P 20010129; US 2002-51770 20020118
IC ICM A61K031-00
ICS A61K031-44; A61K031-70; A61K045-06
AB US2002103109 A UPAB: 20021014
NOVELTY - Method (M1) for treating an addiction disorder comprises administering a first alpha-3 beta-4 nicotinic receptor antagonist (I) and a second alpha-3 beta-4 nicotinic receptor antagonist (II), where (II) is different from (I). (I) and (II) are administered simultaneously or non-simultaneously.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) a composition comprising (I) and (II), where (I) and (II) are different;

(2) method (M2) of evaluating a compound for its effectiveness in treating addiction disorders comprising assessing the compounds ability to bind to alpha-3 beta-4 nicotinic receptors; and

(3) method (M3) for treating an addiction disorder comprising administering an alpha-3 beta-4 nicotinic receptor antagonist.

ACTIVITY - Antiaddictive; Antismoking; Antialcoholic.

Test details are described but no suitable results are given.

MECHANISM OF ACTION - Alpha-3 beta-4 nicotinic receptor antagonist.

USE - For treating addiction disorders, e.g. nicotine, opioid, heroin, amphetamine, cocaine and alcohol addiction, (all claimed).

Dwg.0/14

FS CPI

FA AB; DCN

MC CPI: B06-D18; B10-B04B; B14-L06; B14-M01A; B14-M01B; B14-M01C

TECH UPTX: 20021014

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Method (M1): When (I) and (II) are administered sequentially there is preferably 4 hours between each administration.

Preferred Composition: (I) and (II) are present in weight ratio of 10:1 - 1:10 (preferably 5:1 - 1:5). The composition is in the form of a tablet, capsule, granular dispersible powder, suspension, syrup or elixir. The composition further comprises inert diluent, granulating agent, disintegrating agent and/or lubricating agent.

Preferred Method (M2): The method involves contacting the test compound with the alpha-3 beta-4 nicotinic receptor and determining the amount of test compound which binds to the receptor.

Preferred Method (M3): The method specifically excludes the use of **mecamylamine, 18-methoxycoronaridine, bupropion, dextromethorphan,** dexrorphan or **ibogaine**. The alpha-3 beta-4 nicotinic receptor antagonist is specific or selective for alpha-3 beta-4 nicotinic receptors and is more potent than **18-methoxycoronaridine** at the receptors.

ABEX

SPECIFIC COMPOUNDS - Use of 5 compounds in the composition and (M1) is specifically claimed, i.e. **mecamylamine, 18-methoxycoronaridine, bupropion, dextromethorphan** and **dextrorphan** (preferably (I) is **mecamylamine** and (II) is dexromethorphan).

ADMINISTRATION - (I) and (II) are administered in dosages of 0.01-10 (preferably 0.1-5) mg/kg/day. Administration of (I) and (II) can be individually or together, orally or parenterally (e.g. intraventricular, intracerebral, intramuscular, intravenous, intraperitoneal, rectal and subcutaneous administration).

L156 ANSWER 2 OF 5 WPIX (C) 2003 THOMSON DERWENT

AN 2001-514499 [56] WPIX

DNC C2001-153730

TI Treating addiction to substances e.g. alcohol, nicotine and inhalant solvents comprises administering mu-opioid receptor antagonist, calcium channel blocker and NMDA-glutamate receptor modulator.

DC B05

IN SCHULMAN, A; SHULMAN, A

PA (SHUL-I) SHULMAN A; (SCHU-I) SCHULMAN A

CYC 95

PI WO 2001052851 A1 20010726 (200156)* EN 46p A61K031-485

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE

SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
AU 2001026574 A 20010731 (200171) A61K031-485
NO 2002003482 A 20020919 (200275) A61K000-00
EP 1250136 A1 20021023 (200277) EN A61K031-485
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR

ADT WO 2001052851 A1 WO 2001-AU60 20010122; AU 2001026574 A AU 2001-26574 20010122; NO 2002003482 A WO 2001-AU60 20010122, NO 2002-3482 20020722; EP 1250136 A1 EP 2001-901062 20010122, WO 2001-AU60 20010122

FDT AU 2001026574 A Based on WO 200152851; EP 1250136 A1 Based on WO 200152851

PRAI AU 2000-2237 20001221; GB 2000-1390 20000122; GB 2000-1647 20000126; AU 2000-22370 20001221

IC ICM A61K000-00; A61K031-485
ICS A61K031-16; A61K031-277; A61K031-4418; A61K031-4422; A61K031-4965; A61K031-554; A61P025-30; A61P025-32; A61P025-34; A61P025-36

AB WO 200152851 A UPAB: 20011001

NOVELTY - Methods of treating substance addiction comprise administering a combination of:

(a) a micro -opioid receptor antagonists (micro ORA);

(b) a calcium channel blocker (CCB) that is long-acting or in sustained release form or that is nimodipine in rapid-release form; and

(c) an N-methyl-D-aspartate (NMDA)-glutamate receptor modulator.

ACTIVITY - Antiaddictive; antialcoholic.

Six detoxified alcoholic patients were treated in an N-of-1 double-blind, placebo-controlled, crossover trial with a daily dose of naltrexone (25 mg), acamprosate (1 g) and amlodipine, felodipiine or verapamil (at the specified or half the specified therapeutic dose. Each patient received sequentially three different, but operationally related treatments, each on an oral once daily basis labeled A (active or control treatment), B (wash out) or C (control or washout treatment). A and C were given for the same and longest length of time available before the trial was terminated. Administration of active and control treatments was always separated by a daily wash out treatment given for 1 week. Scoring of key parameters was based on questionnaires completed by the subject. For the audit score, an initial baseline questionnaire preceding treatment and weekly thereafter was conducted. The participant's answers were assigned a value and the score for all 10 questions totaled (out of 40). A total of 13+ indicated alcohol dependent, 8+ hazardous drinker, less than 8 a safe drinker and 0 total abstinence. Levels of craving, tendency to relapse and degree of abstinence were rated by the participant on a scale of 0,0 (absence of craving, absence of relapse) and 10 (total abstinence from alcohol and volatile inhalant). In two participants, the administered dose of amlodipine (6 mg) gave a number of initial transient side-effects that were generally prevented by the prior administration of 20 mg propranolol, which generally had no effect on blood pressure. One 47-year-old female alcoholic who had a drinking history of 6-10 units per day for 10 years received 25 mg/day naltrexone, 3 multiply 333 mg/day acamprosate and placebo for 5 weeks, 25 mg/day naltrexone and 3 multiply 333 mg/day acamprosate for 1 week and 25 mg/day naltrexone, 3 multiply 333 mg/day acamprosate and 5 mg/day amlodipine for 5 weeks. Her baseline scores were audit = 30, craving = 9, relapse = 2 and abstinence = 0. Her weekly scores were: audit = 18, 17, 14, 14, 14, 14, 12, 11, 13, 13 and 5 for weeks 2-12, respectively; craving = 0 for all weeks; relapse = 0 for all weeks; and abstinence = 10 for all weeks. Weekly side-effects were minimal, nil, minimal, nil, nil, nil, nil, moderate for 2 days), mild, nil and nil. Improved ancillary parameters were: energy =1+ for weeks 2-10, 1++ for week 11 and 1+++ for week 12; thinking = 1+ for weeks 2-10, 1++ for week 11 and 1+++ for week 12; and in control = 1+ for weeks 2-10, 1++ for week 11 and 1+++ for week 12. In the patient's view, her progress was progress+ for weeks 2-10, progress++ for week 11 and progress +++ for week 12.

MECHANISM OF ACTION - micro -opioid receptor antagonist; calcium channel blocker; NMDA-glutamate receptor modulator; ganglion nicotinic receptor antagonist; nicotinic cholinergic receptor antagonist or a

kappa-opioid agonist.
USE - The methods are used to treat substance addiction, including addiction to alcohol, solvent inhalant or alcohol and/or one or more other addictive substances such as nicotine, opiates or solvent inhalants.
Dwg.0/0

FS CPI
FA AB; DCN
MC CPI: B04-A03; B04-A04; B06-D18; B06-E03; B06-F03; B07-D04D; B07-D05; B09-D01; B10-A15; B10-B02E; B14-M01; B14-M01A; B14-M01C
TECH UPTX: 20011001
TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Method: The microORA is naltrexone (25 mg once daily (od)), nalmefine, buprenorphine or 1-alpha-acetylmethadol. The NMDA-glutamate receptor modulator is 3-((+/-)-2-carboxypiperizin-4-yl)-propyl-1-phosphonic acid (CCP), dizocilpine, HA966, **ibogaine**, memantine, ifenprodil, eliprodil or acamprostate (333 or 666 mg three times daily (tid) or 1000 mg od or twice daily (bd). The CCB is nifedipine (15-120 mg od), nimodipine (15-60 mg tid or four times daily (qid)), nisoldipine (20-80 mg od or 10-40 mg bd), felodipine (2.5-20 mg od), amlodipine (2.5-20 mg od), darodipine, floridipine, lacidipine (2-8 mg od), isradipine (2.5-20 mg od), niguldipine, niludipine, oxadipine, elgodipine, riodipine, nilvadipine, lemdipine, nitrendipine (5-20 mg od), nicardipine (30-120 mg od or 15-60 mg bd), verapamil (80-480 mg od), diltiazem (90-360 mg od) or flunarizine (10-20 mg od, bd or tid). The CCB is long-acting amlodipine or sustained-release verapamil, nifedipine or felodipine. (a), (b) and/or (c) are adapted for oral administration. The addictive substance is nicotine and the composition further comprises a ganglion nicotinic receptor antagonist such as **mecamylamine**, a nicotinic cholinergic receptor antagonist such as **bupropion**, gamma-vinyl gamma amino butyric acid (GABA) (vigabatrin) or a kappa-opioid agonist.
ABEX
ADMINISTRATION - Administration of the active agents is as combined or discrete doses. Administration may be oral (claimed), parenteral, transdermal or by implantation (e.g. subcutaneous implants). Dosage is dependent on the agents used but may include 25 mg od naltrexone, 333 or 666 mg tid or 1000 mg od or bd acamprostate, 15-120 mg od nifedipine, 15-60 mg tid or qid nimodipine, 20-80 mg od or 10-40 mg bd nisoldipine, 2.5-20 mg od felodipine, 2.5-20 mg od amlodipine, 2-8 mg od lacidipine, 2.5-20 mg od isradipine, 5-20 mg od nitrendipine, 30-120 mg od or 15-60 mg bd nicardipine, 80-480 mg od verapamil, 90-360 mg od diltiazem or 10-20 mg od, bd or tid flunarizine (claimed).

L156 ANSWER 3 OF 5 WPIX (C) 2003 THOMSON DERWENT
AN 2001-514493 [56] WPIX
DNC C2001-153724
TI Nicotinic antagonists in preparation of medicaments adapted for ocular administration, used in control of postnatal ocular growth and treatment and prevention of myopia.
DC B05
IN LINDSTROM, J M; STONE, R A
PA (VALL-N) VALLEY FORGE PHARM INC
CYC 95
PI WO 2001052832 A1 20010726 (200156)* EN 53p A61K031-135
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
AU 2001030969 A 20010731 (200171) A61K031-135
EP 1272170 A1 20030108 (200311) EN A61K031-135
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR

ADT WO 2001052832 A1 WO 2001-US1692 20010118; AU 2001030969 A AU 2001-30969 20010118; EP 1272170 A1 EP 2001-903112 20010118, WO 2001-US1692 20010118
FDT AU 2001030969 A Based on WO 200152832; EP 1272170 A1 Based on WO 200152832
PRAI US 2000-176875P 20000118
IC ICM A61K031-135
ICS A61K031-13; A61K031-44; A61K031-445; A61P027-10
AB WO 200152832 A UPAB: 20011001
NOVELTY - Use of nicotinic antagonists for the preparation of medicaments adapted for ocular administration for the control of postnatal ocular growth.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) a method of inhibiting the abnormal axial growth of the eye of a host animal comprising the step of administering to the eye during postnatal development, nicotinic antagonist to inhibit the abnormal postnatal growth of the eye, or abnormal equatorial expansion of the eye, or abnormal vitreous cavity expansion of the eye;

(2) a method for inhibiting the development of myopia comprising ocular administration of nicotinic antagonist;

(3) methods of detecting the ability of nicotinic antagonists to control postnatal ocular growth by containing a 1st animal eye with a therapeutically effective amount of a nicotinic antagonist, detecting the change in growth of the 1st animal eye, applying a known control agent in a 2nd animal eye, observing the results of the control agent on the change in growth of the 2nd animal eye and comparing the change in growth of the 1st eye with the change in growth of a 2nd eye; and

(4) methods of identifying compounds that can be used to modulate myopia by incubating a cell that expresses a nicotinic receptor in the presence and absence of test compound, determining whether the test compound binds to the nicotinic receptor, selecting a test compound that binds to the nicotinic receptor, administering the selected test compound to a test animal, determining whether the test compound alters the development of myopia and selecting a compound that alters the development of myopia.

ACTIVITY - Ophthalmological.

Cohorts of control chicks wearing unilateral goggles and treated with vehicle developed ipsilateral myopia of -7 to -12 diopters compared with the contralateral non-goggled eyes. The axial lengths in the goggled eyes were increased by 0.4-0.6 mm compared to the contralateral eyes. The axial length difference between goggled and open eyes was greater as measured by ultrasound. The vitreous cavity of goggled eyes was enlarged in both the axial and equatorial dimensions, with vitreous cavity elongation largely accounting for the increase in overall axial length of the eye. Goggle wearing alone induced no significant effect on anterior chamber depth in most cohorts. Chlorisondamine was given every other day to goggled chicks. Chlorisondamine reduced the myopic refractive index (P less than 0.001), inhibited the excessive axial elongation developing beneath the goggle (P less than 0.001 by ultrasound, P=0.008 by calipers) and reduced the vitreous cavity expansion in both axial (P less than 0.001) and equatorial (P=0.001) dimension. Chlorisondamine had no statistically significant effect on anterior chamber depth.

MECHANISM OF ACTION - Nicotinic antagonist.

USE - Nicotinic antagonists are used to prepare medicaments used to control postnatal ocular growth, to inhibit abnormal axial growth, abnormal equatorial expansion and abnormal vitreous cavity expansion of the eyes of host animals during postnatal development and to prevent or treat myopia (claimed).

ADVANTAGE - The nicotinic antagonists are well tolerated following local application in the human eye, without inducing pupil dilation and paralysis of accommodation in children.

Dwg.0/3
FS CPI
FA AB; DCN
MC CPI: B04-A07A; B06-A02; B06-D03; B06-D04; B06-D15; B06-D18; B07-D05;

B10-B03B; B10-B04B; B14-L06; B14-N03
TECH UPTX: 20011001
TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Components: The nicotinic antagonist is a competitive nicotinic antagonist, preferably methyllcaconitine or dihydro-beta-erythroidine, a channel-blocking nicotinic antagonist, preferably **mecamylamine** or chlorisondamine, a noncompetitive nicotinic antagonist, preferably sertraline, paroxetine, nefaxodone, venlafaxine, fluoxetine, **bupropion**, phencyclidine or **ibogaine**, an antibody inhibiting nicotine receptor function or an agonist that acts like a nicotinic antagonist.
ABEX
ADMINISTRATION - Administration is ocular (claimed) in the form of eye drops as well as parenteral, enteral or topical. Administration is to mammals including humans as well as birds, monotremes, reptiles and fish. Eye drops contain 0.005-10 (0.01-5; 0.1-2)%. Dosage regimen is 1-4 times/day spaced evenly throughout the waking hours.

L156 ANSWER 4 OF 5 WPIX (C) 2003 THOMSON DERWENT
AN 2001-079494 [09] WPIX
DNC C2001-022743
TI Compositions comprising antagonists in combination with nicotinic acid, opioid agonists, anti-depressants, stimulants, NSAIDS and local anaesthetics are useful in treating excitable system disorders, pain and psychiatric disorders.
DC B02 B05
IN HAMANN, S R
PA (KENT) UNIV KENTUCKY RES FOUND
CYC 1
PI US 6153621 A 20001128 (200109)* 26p A61K031-44
ADT US 6153621 A Provisional US 1997-50557P 19970623, US 1998-102089 19980623
PRAI US 1997-50557P 19970623; US 1998-102089 19980623
IC ICM A61K031-44
ICS A61K031-13
AB US 6153621 A UPAB: 20010213
NOVELTY - Combined antagonist compositions in combination with nicotinic acid, opioid agonists, anti-depressants, stimulants, NSAIDS and local anaesthetics are useful in treating excitable system disorders, pain and psychiatric disorders.
DETAILED DESCRIPTION - A composition for the treatment of excitable system abnormalities, pain and psychiatric disorders comprises synergistic amounts of **mecamylamine** and naltrexone in a carrier.
ACTIVITY - Analgesic; antidrug.
MECHANISM OF ACTION - None given.
USE - The composition is administered to provide increased or decreased excitable system activity in the patient and is useful for treating pain, drug abuse and underlying psychopathologies.
ADVANTAGE - The treatments are devoid of abuse potential.
Dwg.0/34
FS CPI
FA AB; DCN
MC CPI: B04-A03; B04-A04; B06-A03; B06-D01; B06-D04; B06-D08; B06-D12; B06-D16; B06-D18; B06-F02; B06-F05; B07-B01; B07-D02; B07-D04C; B07-D05; B07-E01; B08-C01; B08-D01; B10-A10; B10-B03B; B10-B04B; B10-C04C; B10-C04D; B10-D03; B14-C01; B14-J01; B14-M01; B14-M01C
TECH UPTX: 20010213
TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Composition: The mecmylamine and naltrexone are present in a dosage of up to 0.25 mg/kg each. The composition comprises opioid antagonist(s) and nicotinic antagonist(s) (especially naltrexone and **mecamylamine**
ABEX
ADMINISTRATION - Orally, nasally, rectally, intravenously, epidurally or intrathecally.

EXAMPLE - The opioid antagonist, naltrexone and nicotinic antagonist, **mecamylamine** were administered in dosage up to 0.25 mg/kg each. When treated with the combination the patient exhibited stabilized system activity with less excitory influence.

L156 ANSWER 5 OF 5 WPIX (C) 2003 THOMSON DERWENT
AN 1999-277208 [23] WPIX
DNC C1999-081401
TI Composition and methods for treating tobacco, nicotine, cocaine and alcohol addiction.
DC B05
IN CARY, D D
PA (CARY-N) CARY MEDICAL CORP
CYC 27
PI WO 9917803 A1 19990415 (199923)* EN 30p A61K045-06
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
W: AU BR CA CN JP KR SG US
AU 9896011 A 19990427 (199936)
EP 1019088 A1 20000719 (200036) EN A61K045-06
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
BR 9812615 A 20000801 (200043) A61K045-06
US 6197827 B1 20010306 (200115) A61K031-00
CN 1280505 A 20010117 (200128) A61K045-06
US 2001014678 A1 20010816 (200149) A61K031-553
KR 2001030860 A 20010416 (200163) A61K045-06
JP 2001518520 W 20011016 (200176) 33p A61K045-06
AU 750808 B 20020725 (200260) A61K045-06
EP 1019088 B1 20030212 (200313) EN A61K031-135
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
ADT WO 9917803 A1 WO 1998-US20894 19981002; AU 9896011 A AU 1998-96011 19981002; EP 1019088 A1 EP 1998-949758 19981002, WO 1998-US20894 19981002; BR 9812615 A BR 1998-12615 19981002, WO 1998-US20894 19981002; US 6197827 B1 Provisional US 1997-60794P 19971003, WO 1998-US20894 19981002, US 1999-423897 19991116; CN 1280505 A CN 1998-811814 19981002; US 2001014678 A1 Provisional US 1997-60794P 19971003, Div ex WO 1998-US20894 19981002, Div ex US 1999-423897 19991116, US 2001-785496 20010220; KR 2001030860 A KR 2000-703540 20000331; JP 2001518520 W WO 1998-US20894 19981002, JP 2000-514672 19981002; AU 750808 B AU 1998-96011 19981002; EP 1019088 B1 EP 1998-949758 19981002, WO 1998-US20894 19981002
FDT AU 9896011 A Based on WO 9917803; EP 1019088 A1 Based on WO 9917803; BR 9812615 A Based on WO 9917803; US 6197827 B1 Based on WO 9917803; US 2001014678 A1 Div ex US 6197827; JP 2001518520 W Based on WO 9917803; AU 750808 B Previous Publ. AU 9896011, Based on WO 9917803; EP 1019088 B1 Based on WO 9917803
PRAI US 1997-60794P 19971003; US 1999-423897 19991116; US 2001-785496 20010220
IC ICM A61K031-00; A61K031-135; A61K031-553; A61K045-06
ICS A61K031-164; A61K031-505; A61K031-55; A61K031-554; A61P025-32; A61P025-34; A61P025-36
AB WO 9917803 A UPAB: 20011203
NOVELTY - A composition for treating tobacco addiction or nicotine addiction, palliating nicotine withdrawal symptoms and facilitating smoking cessation comprises a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for:
(i) a method of treating tobacco or nicotine addiction, palliating nicotine withdrawal and facilitating smoking cessation;
(ii) a composition for treating cocaine addiction and withdrawal effects;
(iii) a method of treating cocaine addiction and withdrawal effects;
(iv) a composition for treating alcohol dependence and withdrawal effects;

(v) a method for treating alcohol dependence and withdrawal effects.
ACTIVITY - Nicotine antagonist.
MECHANISM OF ACTION - None given.
USE - The composition and method are useful for treating tobacco, nicotine, cocaine and alcohol addiction, palliating nicotine, cocaine or alcohol withdrawal and facilitating smoking cessation.
Dwg.0/0
FS CPI
FA AB; DCN
MC CPI: B05-C07; B06-A02; B06-A03; B06-D03; B06-D08; B06-D12; B06-D18; B06-E05; B06-F05; B07-D05; B07-D11; B07-D12; B08-C01; B08-D01; B09-D01; B10-A09B; B10-A12C; B10-A18; B10-A19; B10-A21; B10-B02G; B10-B03B; B10-B04B; B14-M01A; B14-M01B; B14-M01C
TECH UPTX: 19990616
TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The composition contains 50-300 (especially 50-150) mg of **bupropion**, 1-25 (especially 1-10) mg of **mecamylamine** or 5-60 (especially 5-10) mg of buspirone.
Preferred Drugs: The anti-depressant is **bupropion**, doxepin, desipramine, clomipramine, imipramine, nortriptyline, amitriptyline, protriptyline, trimipramine, fluoxetine, fluvoxamine, paroxetine, sertraline, phenelzine, tranylcypromine, amoxapine, maprotiline, trazodone, venlafaxine or mirtazapine. The nicotine receptor antagonist is **mecamylamine**, amantadine, pempidine, dihydro-beta-erythroidine, hexamethonium, erysodine, chlorisondamine, trimethaphan camsylate, tubocurarine chloride or d-tubocurarine. The anti-anxiety agent is hydroxyzine, meprobamate or buspirone.
ABEX
EXAMPLE - A typical composition contained **mecamylamine** (1.0mg) and **bupropion** (50mg) and was administered 1-6 times daily.

=> d his

(FILE 'HOME' ENTERED AT 15:45:16 ON 10 MAR 2003)
SET COST OFF

FILE 'REGISTRY' ENTERED AT 15:45:26 ON 10 MAR 2003
L1 4 S (ETHANOL OR COCAINE OR NICOTINE OR HEROIN)/CN
L2 251 S (COCAINE OR NICOTINE OR HEROIN) AND (C17H21NO4 OR C21H23NO5 O
L3 72 S L2 AND 1/NC
L4 36 S L3 NOT (LABELED OR ION OR (D OR T)/ELS OR 11C# OR 13C# OR 14C
L5 33 S L4 NOT BUTEN
E MECAMYLAMINE/CN
L6 1 S E3
E 18-METHOXYCORONARIDINE/CN
L7 1 S E3
L8 12 S C22H28N2O3/MF AND IBOGAMIN?
L9 3 S L8 AND 18 AND 21
E BUPROPION/CN
L10 1 S E3
L11 7 S C13H18CLNO/MF AND 46.150.18/RID AND 1 PROPANONE AND 3 CHLOROP
L12 6 S L11 NOT (DIETHYLAMIN OR D/ELS)
L13 5 S L12 NOT DIETHYLAMINO
E DEXTR4OMETHORPHAN/CN
E DEXTROMETHORPHAN/CN
L14 1 S E3
L15 7 S C18H25NO/MF AND MORPHINAN AND 3 METHOXY 17 METHYL
L16 4 S L15 NOT (T/ELS OR LABELED OR ION)
E DEXTRORPHAN/CN
L17 1 S E3
L18 7 S C17H23NO/MF AND MORPHINAN 3 OL AND 17 METHYL
L19 5 S L18 NOT (LABELED OR D/ELS)

```
                E IBOGAINE/CN
L20           1 S E3
L21           8 S C20H26N2O/MF AND IBOGAMINE AND 12 METHOXY
L22           3 S L21 NOT (D OR T)/ELS
L23           2 S L22 NOT 50838-05-6
L24          20 S L6,L7,L9,L10,L13,L14,L16,L17,L19,L20,L23
                SEL RN
L25         136 S E1-E20/CRN
L26          66 S L25 NOT (MXS/CI OR COMPD OR WITH)
L27          64 S L26 NOT CONJUGATE
L28          70 S L25 NOT L26

     FILE 'HCAPLUS' ENTERED AT 16:03:09 ON 10 MAR 2003
L29        3562 S L24
L30         929 S L27
L31        5187 S MECAMYLAMINE OR 18 METHOXYCORONARIDINE OR BUPROPION OR DEXTRO
L32         817 S LEVORPHANOL
L33        6425 S L29-L32
                E NICOTINIC RECEPTOR/CT
                E E6+ALL
L34          76 S E77,E78,E76 (L) (ALPHA3BETA4 OR (ALPHA3 OR ALPHA 3)(L)(BETA4
                E NICOTINIC ANTAGONIST/CT
                E E4+ALL
L35           4 S E7,E8,E6 (L) (ALPHA3BETA4 OR (ALPHA3 OR ALPHA 3)(L)(BETA4 OR
L36          19 S L33 AND L34,L35
L37          76 S L34,L35,L36
                E NICOTINIC RECEPTOR/CT
                E E6+ALL
L38        7380 S E77,E78,E76
                E E89+ALL
L39         415 S E7,E8,E6
L40        7577 S L38,L39
L41         276 S L40 AND (ALPHA3BETA4 OR (ALPHA3 OR ALPHA 3)(L)(BETA4 OR BETA
L42           2 S L40 AND (A3(L)B4)
L43          43 S L33 AND L41,L42
L44         100 S L37,L43
L45         277 S L41-L44
L46          43 S L33 AND L45

     FILE 'REGISTRY' ENTERED AT 16:09:55 ON 10 MAR 2003
L47           1 S 467-77-6
L48           2 S 467-77-6/CRN

     FILE 'HCAPLUS' ENTERED AT 16:10:10 ON 10 MAR 2003
L49         190 S L47,L48
L50          43 S L33,L49 AND L45
                E DRUG DEPENDENCE/CT
L51       11335 S E3+NT OR E4
                E E3+ALL
                E E10+ALL
L52        3691 S E3,E4
L53       39645 S E3+NT
L54           4 S L50 AND L51,L52,L53

     FILE 'REGISTRY' ENTERED AT 16:16:00 ON 10 MAR 2003
L55           2 S (MORPHINE OR METHAMPHETAMINE)/CN
L56          15 S C17H19NO3/MF AND MORPHINAN 3 6 DIOL AND 7 8 DIDEHYDRO AND 4 5
L57           8 S L56 NOT (LABELED OR 11C# OR (D OR T)/ELS)
L58           7 S L57 NOT 14C#
L59           8 S C10H15N/MF AND 46.150.18/RID AND BENZENEETHANAMINE AND ALPHA
L60           4 S L59 AND N
L61           3 S L60 NOT D/ELS
L62          10 S L55,L58,L61
```

```
                SEL RN
L63           238 S E1-E10/CRN
L64            59 S L63 NOT ((MXS OR IDS)/CI OR COMPD OR WITH OR CONJUGATE)
L65            58 S L64 NOT B/ELS
L66           272 S L1,L5,L63,L65
                SEL RN L6
L67            10 S E11/CRN
L68             4 S L67 AND MXS/CI
                SEL RN 1 2
L69             2 S E12-E13
L70            39 S L28 AND MXS/CI

     FILE 'HCAPLUS' ENTERED AT 16:24:32 ON 10 MAR 2003
L71             1 S L69
L72             3 S L54 NOT ACETYLCHOLINE/TI
L73          6558 S L33,L47,L48
L74        188417 S L1,L5,L62
L75        916746 S ALCOHOL OR ETHANOL OR ETHYL ALCOHOL OR NICOTINE OR OPIOID OR
L76         85289 S TOBACCO OR SMOKINE OR SMOKE OR SNUFF OR CIGAR?
L77          3304 S L73 AND L74-L76
L78          1084 S L77 AND L51-L53
L79         59019 S L74-L76 AND (ADDICT? OR ABUS? OR WITHDRAW? OR ALCOHOLISM OR (
L80           755 S L73 AND L79
L81          1417 S L78,L80
L82           520 S L81 AND (MIX? OR ADMIX? OR COMBIN? OR SYNERG? OR COMPOSITION
L83            45 S L82 AND L40
L84             2 S L82 AND L37,L41-L45
L85             3 S L72,L84
L86            43 S L83 NOT L85
L87          6558 S L33,L49
L88          3314 S L87 AND (L74 OR L75 OR L76 OR SMOKING)
L89          2253 S L87 AND (MIX? OR ADMIX? OR COMBIN? OR SYNERG? OR COMPOSITION
L90          4446 S L88,L89
L91            45 S L90 AND (ALPHA3BETA4 OR (ALPHA3 OR ALPHA 3 OR A3)(L)(BETA4 OR
L92           607 S L90 AND L40
L93            37 S L91 AND L92
L94             0 S L93 NOT L83-L86,L46,L50
                SEL DN AN L83 8
                SEL DN AN L83 9
L95             1 S E17-E19 AND L83
L96             4 S L85,L95 AND L29-L46,L49-L54,L71-L95
L97             4 S L96 AND L1,L5,L24,L27,L47,L48,L62,L65,L66,L69

     FILE 'REGISTRY' ENTERED AT 16:42:48 ON 10 MAR 2003
L98             1 S 300-62-9
L99           100 S 300-62-9/CRN
L100           85 S L99 NOT MXS/CI
L101           18 S L100 NOT (COMPD OR WITH OR CONJUGATE)
L102           17 S L101 NOT CR/ELS

     FILE 'HCAPLUS' ENTERED AT 16:43:46 ON 10 MAR 2003
L103            1 S L98,L102 AND L97
L104            1 S L97 AND AMPHETAMINE
L105            4 S L97,L103,L104

     FILE 'HCAPLUS' ENTERED AT 16:44:19 ON 10 MAR 2003
                SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 16:44:43 ON 10 MAR 2003
L106           21 S E20-E40

     FILE 'REGISTRY' ENTERED AT 16:44:50 ON 10 MAR 2003
```

```
     FILE 'MEDLINE' ENTERED AT 16:45:08 ON 10 MAR 2003
                E NICOTINIC RECEPTOR/CT
                E E4+ALL
                E E2+ALL
L107         6418 S E8+NT
L108          314 S NICOTINIC RECEPTOR ANTAGONIST
L109         3352 S NICOTINIC RECEPTOR
L110          705 S ALPHA3BETA4 OR (ALPHA3 OR ALPHA 3 OR A3)(L)(BETA4 OR BETA 4 O
L111          266 S L107-L109 AND L110
                E SUBSTANCE ABUSE/CT
                E E3+ALL
                E E2+ALL
L112       131335 S E5+NT
                E E75+ALL
L113        63818 S E6+NT
                E E36+ALL
L114         1695 S E27+NT
                E STREET DRUGS/CT
                E E3+ALL
L115         4241 S E4+NT
L116            1 S L111 AND L112-L115
L117         3430 S L24 OR L47
L118         5110 S L31 OR L32
L119          379 S L112-L115 AND L117,L118
                E DRUG COMBINATION/CT
L120        34971 S E6+NT
                E DRUG THERAPY, COMBINED/CT
                E DRUG THERAPY, COMBINATION/CT
L121        72418 S E3+NT
L122           26 S L119 AND L120,L121
L123            6 S L122 NOT AB/FA
L124           20 S L122 NOT L123
                E NICOTINIC ANTAGONIST/CT
L125        17037 S E4+NT
L126          102 S L125 AND L112-L115
                E TOBACCO/CT
                E E3+ALL
L127           14 S L125 AND E6+NT
L128           55 S L125 AND E11+NT
L129           17 S L125 AND E12+NT
L130            9 S L126-L129 AND L120,L121
L131            9 S L130 AND L107-L130
L132         1910 S MECAMYLAMINE
L133           11 S L132 AND (DEXTROMETHORPHAN OR DEXTRORPHAN OR BUPROPION OR IBO
                SEL DN AN 3 6
L134            2 S L133 AND E1-E6
L135            2 S L134 AND L107-L134

     FILE 'MEDLINE' ENTERED AT 17:01:04 ON 10 MAR 2003

     FILE 'WPIX' ENTERED AT 17:01:10 ON 10 MAR 2003
L136           27 S L132/BIX
                E MECAMYLAMINE/DCN
                E E3+ALL
L137           27 S E2
L138            3 S E4
L139           33 S L136-L138
L140          403 S (DEXTROMETHORPHAN OR DEXTRORPHAN OR BUPROPION OR IBOGAINE OR
                E DEXTROMETHORPHAN/DCN
                E E3+ALL
L141          222 S E2
L142          106 S E4
L143            1 S E6
```

```
L144          1 S E8
L145        113 S E10
L146          1 S E12
                E DEXTRORPHAN/DCN
                E E3+ALL
L147         35 S E2
L148         17 S E4
L149          1 S E6
                E BUPROPION/DCN
                E E3+ALL
L150         58 S E2
L151         23 S E4
                E IBOGAINE/DCN
                E E3+ALL
L152         12 S E2
L153          2 S E4
L154          3 S E6
                E 18-METHOXYCORONARIDINE/DCN
                E METHOXYCORONARIDINE/DCN
                E 18 METHOXYCORONARIDINE/DCN
L155          7 S L139 AND L140-L154
L156          5 S L155 NOT (POLYMER OR SKIN)/TI

     FILE 'WPIX' ENTERED AT 17:07:42 ON 10 MAR 2003
```